Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 73 EV-to-EBIT is 8.93 as of Sep. 21, 2026, which is 1% below its 10-year median of 8.98. GuruFocus rates ROCO:3118 with a GF Score™ of 73/100 and a GF Value™ of NT$33.07 (Fairly Valued). The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Level Biotechnology ranks better than 59.32% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Level Biotechnology's Enterprise Value for the quarter that ended in Jun. 2026 was NT$846.5 Mil.
Level Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$94.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology EV-to-EBIT Related Terms
Level Biotechnology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Level Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's EV-to-EBIT falls into.
Level Biotechnology's current Enterprise Value is NT$839.1 Mil.
Level Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$94.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a EV-to-EBIT of 8.93 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Level Biotechnology and its competitors. This is near median its historical median of 8.98. Over the past decade, Level Biotechnology's EV-to-EBIT has ranged from 5.18 to 15.16. According to the industry distribution chart, Level Biotechnology ranks #155 out of 381 companies in the Biotechnology industry, placing it in the top 40.7%.
Is Level Biotechnology's EV-to-EBIT too high?
Level Biotechnology's current EV-to-EBIT of 8.93 is near median its 10-year median of 8.98. Over the past 10 years, this metric has ranged from a low of 5.18 to a high of 15.16. The Biotechnology industry median EV-to-EBIT is 14.12. Level Biotechnology's value of 8.93 is 36.8% below this industry median. Based on the distribution chart, Level Biotechnology ranks #155 out of 381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #155 out of 381 companies for EV-to-EBIT. This puts Level Biotechnology in the upper half of its industry. The industry median EV-to-EBIT is 14.12. Level Biotechnology's value of 8.93 is 36.8% below this benchmark. Historically, Level Biotechnology's own EV-to-EBIT has ranged from 5.18 to 15.16 over the past decade. While the company's 10-year median is 8.98 vs. the industry median of 14.12, Level Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.12, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current EV-to-EBIT of 8.93 is 36.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current EV-to-EBIT is 8.93, which is near median its own 10-year median of 8.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.07, compared to a current price of NT$31.65 — trading 4.3% below its estimated fair value. The current EV-to-EBIT is 8.93, which is near median its 10-year median of 8.98 and 36.8% below the Biotechnology industry median of 14.12. Level Biotechnology's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current EV-to-EBIT is 8.93 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.65 is trading 4.3% below its estimated GF Value™ of NT$33.07.
GuruFocus considers Level Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3118:
EV-to-EBIT: 8.93 (near median its 10-year median of 8.98)
GF Value™: NT$33.07 vs. price of NT$31.65 (4.3% below fair value)
Industry Position: 36.8% below the Biotechnology median (#155 of 381)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
73GF Score
Get the complete analysis for ROCO:3118
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
